Key result
Titin truncating variants are a common genetic cause of dilated cardiomyopathy, and novel model systems such as iPSC-CMs and CRISPR/Cas9 are advancing the understanding of their pathomechanisms.
Why the study?
Truncating variants in titin are commonly found in patients with dilated cardiomyopathy, highlighting the need to evaluate titin variants and disease mechanisms in cardiomyopathies.
This review highlights the role of titin truncating variants in dilated cardiomyopathy and discusses how model systems and CRISPR technology can advance understanding of disease mechanisms.
Titin variants support expanded genetic panels in cardiomyopathy; leaves open how models inform targeted therapies.
Titin, the largest protein known, has attracted a lot of interest in the cardiovascular field in recent years, since the discovery that truncating variants in titin are commonly found in patients with dilated cardiomyopathy. This review will discuss the contribution of variants in titin to inherited cardiac conditions (cardiomyopathies) and how model systems, such as animals and cellular systems, can help to provide insights into underlying disease mechanisms. It will also give an outlook onto exciting technological developments, such as in the field of CRISPR, which may facilitate future research on titin variants and their contributions to cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
Azad et al. (2019) conducted a review in Cardiomyopathies. Titin truncating variants (TTNtv) was evaluated. Titin truncating variants are a common genetic cause of dilated cardiomyopathy, and novel model systems such as iPSC-CMs and CRISPR/Cas9 are advancing the understanding of their pathomechanisms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: